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AbstrAct:
Astaxanthin is a carotenoid that is present in high quantities in the meat of fish like salmon and the 
shells of shrimp and crab. It exhibits free radical scavenging antioxidant activity when consumed di-
etarily. Astaxanthin is absorbed by the small intestine before exerting its antioxidant effect; however, 
a portion of dietary intake remains unabsorbed in the digestive tract and reaches the large intes-
tines . We hypothesized that astaxanthin may exert its antioxidant action in the large intestine to 
influence the gut microbiota. In this review we introduce the results of two studies of astaxanthin. 
Firstly, a clinical trial targeting post-menopausal women screened for high oxidative stress burden. 
Astaxanthin was administered orally for eight weeks in order to examine its effects and safety, and 
subjects were surveyed for any changes in subjective symptoms. Secondly, in a mouse model, real 
time PCR (polymerase chain reaction) was used to examine the ability of astaxanthin to prevent 
changes in the enteric flora induced by a high-fat diet. When fat intake increases due to changes in 
diet, the equilibrium between the various species that constitute the intestinal flora is altered. As a 
result, degenerative changes in lifestyle-related disease and aging of the host are promoted. Here we 
find that the intake of astaxanthin was able to inhibit these changes in the gut microbiota of mice 
induced by a high-fat diet. Even in humans, it is highly probably that the unabsorbed astaxanthin 
that remains in the intestinal tract exerts a positive effect against disturbance of the intestinal flora 
caused by a high-fat diet.
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Sažetak:
Disbioza inducirana dijetom bogatom mastima & Amelioracija pomoću astaksantina
Astaksantin je karotenoid prisutan u velikom količinama u mesu riba poput lososa i oklopima 
kozica i rakova. Kada se uzima kao hrana ispoljava svoju sposobnost hvatanja slobodnih radikala 
i antioksidativnog djelovanja. Prije no što započne svoje antioksidativno djelovanje apsorbira se 
preko tankog crijeva, međutim , dio ostaje neapsorbiran i dospijeva u debelo crijevo. Razmatrali 
smo mogućnost da astaksantin pomoću svojih antioksidativnih svojstava može utjecati na crijevnu 
mikrobiotu. U okviru ovog preglednog rada osvrnut ćemo se na rezultate dvaju istraživanja. Prvo je 
kliničko ispitivanje usmjereno na postmenopauzalne žene koje su prošle screening na opterećenost 
oksidativnim stresom. Astaksantin  su dobivale oralno kroz 8 tjedana kako bi se procijenili njegovi 
učinci i sigurnost, a ispitanice su anketirane vezano za promjene u subjektivnim simptomima. Dru-
gi, mišji model, koristio je PCR (Lančanu reakciju polimeraze) u pravom vremenu kako bi ispitao 
potencijal astaksantina u sprječavanju promjena u crijevnoj flori induciranih dijetom bogatom mas-
tima. Pri dijeti bogatoj mastima povećava se unos masti  što narušava ravnotežu raznih vrsta  koje 
sačinjavaju intestinalnu floru. Posljedična neravnoteža rezultira degenerativnim promjenama i boles-
tima vezanima za način života. U ovom istraživanju nalazimo da unos astaksantina može spriječiti 
promjena u mikrobioti miševa izazvane prehranom bogatom mastima. Čak i u ljudi je za vjerovati 
da neapsorbirani astaksantin koji ostaje u debelom crijevu ima pozitivan učinak protiv poremećaja 
uzrokovanih prehranom bogatom mastima.
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introduction
Astaxanthin is a carotenoid that is present in high quantities in the 
meat of fish like salmon and the shells of shrimp and crab1. It has 
attracted much attention in the field of preventative medicine for its 
effects against various lifestyle-related illnesses, its anti-fatigue action, 
and general health improving properties2. Astaxanthin is also garner-
ing attention as an ingredient in supplements, for which it is natural-
ly produced by the microalgae Haematococcus pluvialis. Astaxanthin 
exhibits free radical scavenging antioxidant activity when consumed 
dietarily3,4. Previously we performed an open-label non-controlled 
study examining the safety and efficacy of eight-week oral astaxan-
thin intake in post-menopausal women with high oxidative stress 
burden, demonstrating increased antioxidant capacity, lower blood 
pressure, and improvement of constipation and menopause symp-
toms5. Astaxanthin is absorbed by the small intestine before exerting 
its antioxidant effect; however, a portion of dietary intake remains 
unabsorbed in the digestive tract and reaches the large intestines6-8. 
We hypothesized that astaxanthin may exert its antioxidant action in 
the large intestine to influence the gut microbiota (enteric flora), and 
are continuing research into the phenomenon.
The enteric flora changes with age and lifestyle/environment9,10, and 
is associated with overall health and the incidence of carcinogenesis. 
Every individual’s intestinal tract is inhabited by a characteristic 
ecosystem of bacteria that collectively forms the gut microbiome. 
Normally there is equilibrium between the gut microbiota and host, 
as well as between bacterial species. When this balance is disrupted, 
dysbiosis11 and opportunistic infections occur, greatly influencing 
aging12, nutrition13, the efficacy of medication14,15, physiological func-
tion16, immune function17, and carcinogenesis18-20 of the host.
In this review we introduce the results of two studies of astaxanthin. 
Firstly, a clinical trial5 targeting post-menopausal women screened 
for high oxidative stress burden. Astaxanthin was administered orally 
for eight weeks in order to examine its effects and safety, and subjects 
were surveyed for any changes in subjective symptoms. Secondly, in 
a mouse model, real time PCR (polymerase chain reaction)21-23 was 
used to examine the ability of astaxanthin to prevent changes in the 
enteric flora induced by a high-fat diet24.
clinical Study MethodS
In this study, participants were screened in order to select those with 
high oxidative stress. The screening test measured diacron-reactive 
oxygen metabolites (d-ROM) as an indicator of the intensity of oxi-
dative stress burden. From an initial group of 35 healthy post-meno-
pausal women (d-ROM = 362.3 ± 51.4 CARR U), 14 with low 
d-ROM scores were excluded, and the remaining group of 21 partic-
ipants (d-ROM = 387.4 ± 32.4 CARR U) with high oxidative stress 
burden comprised the participants of this study. Participants took 
two 6 mg astaxanthin soft capsules ([AstaReal ACT] Fuji Chemical 
Industry Co.) per day for 8 weeks.
For the evaluation, symptoms were divided into “physical symptoms” 
and “psychological symptoms” in the Anti-Aging QOL Common 
Questionnaire 25). Participants were asked to rank their severity on a 
scale of one to five. 
Of the 34 surveyed physical symptoms, eight symptoms significantly 
improved after 8 weeks of taking the supplement: “eye fatigue,” “stiff 
shoulders,” “weight gain,” “skin problems,” “constipation,” “hair 
loss,” “grey hair,” and “cold sensitivity” (Table 1). Of 21 psychological 
symptoms, “difficulty falling asleep” improved significantly after 8 
weeks. There was no significant change in the lifestyle habits of the 
participants. 
Improving “constipation” is one of the known benefits of astaxanthin, 
and is commonly reported in post marketing surveillance. Astaxan-
thin also relieves loose stool and diarrhea associated with abnormal 
intestinal fermentation. Its bioavailability is low at 2~5%, with the 
greater majority remaining and acting within the digestive tract. 
Astaxanthin may be exerting antioxidant action, clearing free radicals 
derived from bacterial toxins produced by non-beneficial species, im-
proving the intestinal environment and increasing motility as a result.
experiMental aniMal Study MethodS
The experimental method is as follows24. 20 4-week-old ICR mice 
were raised in individual cages for one week and acclimatized. After 
acclimatization, the mice were weighed and sorted into the following 
4 groups consisting of 5 mice each: ordinary diet (Group C), ordi-
nary diet + astaxanthin (Group CA), high-fat diet (Group H), high 
fat diet + astaxanthin (Group HA).
Labo MR Stock (Nosan Corporation) was used for the ordinary diet, 
and HFD-60 Oriental Yeast Co.) for the high-fat diet. Both types of 
feed were prepared with added astaxanthin (Fuji Chemical Industry 
Co., Ltd.) to achieve a final concentration of 0.02%. The nutri-
tional contents of the ordinary diet consisted of 3.9% fat, 18.8% 
protein, 54.7% carbohydrates, and 6.6% dietary fiber; the high fat 
diet contained 35% fat, 23% protein, 25.3% carbohydrates, and 
6.6% dietary fiber. Feces were collected over 24 hours on the final 
acclimatization day, hereafter designated Day 0. The collected feces 
were stored at −20 °C.
Fecal bacteria were tested using real-time PCR as follows. Feces 
collected on Days 0, 14, and 28 were thawed and weighed before 
drying overnight at room temperature. The following day, dry mass 
was weighed and samples were powderized. Approximately 100 mg of 
each powdered sample was weighed into a microtest tube, and DNA 
was extracted using the QIAamp® DNA Stool Mini Kit (Qiagen). 
DNA solutions were prepared and DNA concentration was measured 
using NanoDrop. 
DNA solutions for total bacteria, Lactobacillus, Streptococcus, 
Clostridium coccoides group, and Clostridium leptum were diluted 
100 times; other targets were adjusted to a final concentration of 20 
μg/μL. Primer sequences were determined in accordance with the 
protocol for the LightCycler® 480 SYBR Green I Master (Roche Di-
agnostics), and real-time PCR analysis was performed following the 
Baseline Week 8
(Physical Symptoms) 
Eye Fatigue 3.1±0.8 2.4±0.8 **
Stiff Shoulders 3.4±1.0 2.9±1.1 **
Weight Gain 2.9±1.4 2.5±1.4 *
Skin Problems 2.5±0.8 2.1±0.8 **
Constipation 2.4±1.2 2.0±1.0 *
Hair Loss 2.3±0.9 1.9±0.8 *
Gray Hair 3.6±0.9 3.1±0.9 *
Cold Sensitivity 2.8±1.0 2.3±1.1 **
(Psychological Symptoms)
Difficulty Falling Asleep 2.1±0.89 1.8±0.8 *
Symptom Score: 1 not at all, 2 a little, 3 moderately, 4 quite a lot, 5 very much.
* p < 0.05, ** p < 0.01 vs. baseline score, paired t-test. Cited from reference 5).
Table 1. Symptom Scores from Anti-Aging QOL Common Questionnaire 
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methods of Matsuki et al. or Endo et al.21-23 Bacteroides, Bifidobacte-
rium, Prevotella, Lactobacillus, Clostridium Coccoides, and Clostrid-
ium leptum were targeted for analysis alongside two phyla, Firmicutes 
and Bacteroidetes, as well as total bacteria. The copy numbers of the 
targets were standardized as a percentage of total bacterial copies.
reSultS of the experiMental Study
Change in body weight, feces color and quantity
Mice administered the high-fat diet demonstrated a significant 
increase in weight (p < 0.05) compared to ordinary diet groups 
(comparing H to C, HA to CA). No significant difference in weight 
was detected in the astaxanthin fed groups. The color of feces changed 
to a grayish white in the high-fat diet group mice, and became a wine 
red after the addition of astaxanthin. The amount of feces collected 
from the high-fat diet groups on Day 28 was significantly reduced (p 
< 0.001).
Fecal DNA Content
The amounts of DNA recovered from feces as measured by Nano-
Drop (mean of Day 0, 14, 28) were: Group C: 89.8 ± 21.5 ng/μL; 
Group CA: 102.7 ± 28.5 ng/μL; Group H: 70.2 ± 21.2 ng/μL; Group 
HA: 66.9 ± 28.4 ng/μL. When compared to the ordinary diet groups 
(Group C and Group CA), the high-fat diet groups (Group H and 
Group HA) tended to have less DNA content (p = 0.001).
Genus Streptococcus (lactic acid bacteria)
Streptococcus comprised less than 16% of the total bacterial count 
(Figure 1). The number of bacteria increased substantially in the ordi-
nary diet, but the change was minor in the high-fat diet (p = 0.028). 
Compared to the ordinary diet, the increase in bacteria in the high-fat 
diet group was extremely small (p = 0.008). With the addition of 
astaxanthin, the bacterial count of Group HA returned to the same 
level as the ordinary diet groups (Groups C and CA) on Day 28. The 
difference with and without astaxanthin in the high-fat diet groups 
was significant (p = 0.044).
The genus Streptococcus is comprised of a variety of gram-positive 
and generally facultative anaerobic bacteria which belongs to the order 
Lactobacillales (lactic acid bacteria). While Streptococcus pneumoniae 
is a well-known pathogenic species (the leading cause of pneumonia), 
many other species are members of the salivary and gut microbiomes. 
At the genus level, depletion of Streptococcus has been observed 
in obese teenagers with high fructose intake26 and in children with 
celiac disease27. Conversely, Streptococcus is reported to increase in 
abundance in the guts of infants with a genetic predisposition for type 
1 diabetes28 as well as in colorectal cancer patients29. The seemingly 
contradictory implications of these different shifts in abundance may 
be due to the specific species which are falling out of balance in each 
situation. 
On the species level, several bacteria are noted in the literature as 
potential probiotics. Streptococcus salivarius is an inhabitant of 
both the oral cavity and the gut: it has been demonstrated to possess 
anti-inflammatory and immuno-regulatory effects30,31. Streptococcus 
thermophilus, another probiotic species, may help to reduce uremic 
toxins caused by dysbiosis in the colon of patients with chronic 
kidney diseases32. As part of a probiotic cocktail together with other 
lactic acid bacteria (IRT5), S. thermophilus has shown efficacity 
in modulating auto-immunity33-35. By increasing the abundance of 
Streptococcus species, astaxanthin may contribute to maintaining the 
microbiome’s homeostasis by promoting the proliferation of these 
beneficial bacteria.
Genus Lactobacillus (lactic acid bacteria)
Lactobacillus comprised less than 3% of total bacterial copy numbers 
(Figure 2). Bacterial count was increased significantly in the high-fat 
diet group (p = 0.004). The ordinary meal groups (groups C and 
CA) also showed a trend of increasing bacterial count on days 14 and 
28. There was no significant difference in the rate of bacterial count 
increase between the ordinary and high fat diets (p = 0.069). The rate 
of increase of bacterial count was shown to significantly increase with 
the addition of astaxanthin (p = 0.031).
The genus Lactobacillus is widely known as a prominent member of 
the lactic acid bacteria and a common source of probiotics. As such, 
a large amount of research has focused on the beneficial effects of 
Lactobacillus species on gut health. In the early days of research into 
the human microbiomes, Lactobacillus was easily cultured from feces 
and mistakenly thought to constitute a majority of the gut microbi-
ome36. With the advent of genomic techniques to detect the countless 
species that are not easily cultivated in the lab (many of which are 
anaerobic), it was realized that Lactobacillus species are in actuality a 
small minority of the total biological diversity of the human gut, and 
many species are only transitory inhabitants that do not maintain a 
permanent presence in the intestinal tract. Despite this, the health 
effects of various Lactobacillus species have been heavily studied and 
numerous benefits have been reported. 
















Figure 1. Putative copy numbers of the genus Streptococcus
Results shown as percent of total bacterial copy number, mean ± standard devia-
tion. C: ordinary diet group, CA: ordinary diet + astaxanthin group, H: high-fat 
diet group, HA: high-fat diet + astaxanthin group, (n = 5 each). The addition 
of astaxanthin increased bacterial count in the high-fat diet group (indicated by 
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caused by a high-fat diet in mouse models37,38. Mice fed L. sakei as a 
probiotic show reduced weight gain and lower serum levels of choles-
terol, triglycerides, and leptin. Serum and fecal levels of short chain 
fatty acids are also increased after ingestion of L. sakei, counteracting 
the reduction seen in high-fat diets.
Lactobacillus plantarum has also been studied in mice fed high-fat 
diets39. When fed the probiotic, mice consuming a high-fat diet again 
experienced reduced weight gain and lower plasma levels of leptin, 
cholesterol, and triglycerides. It is also able to mitigate liver damage 
and weakened intestinal permeability of the intestines caused by 
obesity. Additionally, L. plantarum has been reported to increase the 
diversity of the enteric flora39,40, reduce the severity of colitis41,42, and 
it has also demonstrated anti-tumor effects43. 
Lactobacillus rhamnosus has been shown to decrease the amount of 
colon aberrant crypt foci and reduce pro-carcinogenic biomarkers in 
a rat model44, lower cholesterol45, and improve insulin resistance and 
obesity induced by high-fat diet46.
Lactobacillus casei has demonstrated immunoregulatory activity, 
reducing colorectal cancer46  and breast tumors48 in mice models.
Finally, Lactobacillus acidophilus has many reported beneficial 
effects. It has been found to improve gut dysbiosis, intestinal barrier 
function, and liver pathology in non-alcoholic fatty liver disease49. 
Like several of the previous species, it reduces high-fat diet induced 
obesity and improves insulin resistance46. It also demonstrates an 
anti-inflammatory effect, protecting mice from induced colitis50,51. In 
humans, L. acidophilus has been observed to be significantly reduced 
in the feces of type 2 diabetics52.
Clostridium coccoides Group
The Clostridium coccoides group contributed less than 1.4% of the 
total bacterial count (Figure 3). Bacterial count significantly increased 
from the high-fat diet (p = 0.016). The increase was greater in the 
high-fat diet than the ordinary diet (p = 0.012). The addition of 
astaxanthin was revealed to significantly lower the increase of bacteria 
in the high-fat diet (p = 0.029).
Clostridium is a major genus of anaerobic endo-spore forming 
bacteria53. Several species in the genus are known pathogens, such 
as Clostridium botulinum (the causative pathogen of botulism), 
Clostridium tetani (tetanus) and former member Clostridium difficile 
(now Clostridioides difficile). Conversely, the Clostridium coccoides 
group also contains many bacteria that inhabit the human gut and 
play a considerable role in the intestinal ecosystem by fermenting 
dietary plant polysaccharides. 
As a group, Clostridium has been reported to shift with age, becom-
ing less abundant in the elderly53. This diminishing of Clostridium is 
associated with complications of aging such as frailty, hospitalization, 
and antibiotic treatment. However, Clostridium is also found to be 
elevated in the gut of children with type-1 diabetes, and its abun-
dance is positively correlated with plasma glucose levels54. Clostrid-
ium coccoides group is also significantly increased in the stool of 
obese individuals with metabolic syndrome and its abundance is 
correlated with higher serum levels of triglycerides55. Much like the 
genus Streptococcus, the effects of these shifts in abundance may 
differ depending on the specific species involved. 
At the species level, Clostridium asparagiforme, Clostridium scin-
dens, and Clostridium hylemonae are reported at high frequency 
in the elderly53. C. scindens and C. hylemonae exhibit bile-acid 
7-dehydroxylating activity, producing secondary bile acids which are 
associated with the risk of developing gallstones and colon cancer.
The Clostridium coccoides group also includes other anaerobic 
endo-spore forming bacteria of the human microbiome that are not 
necessarily taxonomically related to the genus Clostridium. Some 
Eubacterium species are also lumped into this group. These are com-
monly probiotic bacteria that are known for producing short-chain 
fatty acids such as butyrate, which exhibit anti-inflammatory and 
immuno-regulatory activity. Generally, Eubacterium abundance fol-
lows the opposite trend of the previously named Clostridium species, 
Figure 2. Putative copy numbers of the genus Lactobacillus
Results shown as percent of total bacterial copy number, mean ± standard devia-
tion. C: ordinary diet group, CA: ordinary diet + astaxanthin group, H: high-fat 
diet group, HA: high-fat diet + astaxanthin group, (n = 5 each). Addition of 
astaxanthin raised bacterial count (indicated by arrows, p < 0.05). Groups com-
pared using Tukey’s multiple comparison test. Cited from reference 24).
Figure 3. Putative copy numbers of the Clostridium coccoides group
Results shown as percent of total bacterial copy number, mean ± standard devia-
tion. C: ordinary diet group, CA: ordinary diet + astaxanthin group, H: high-fat 
diet group, HA: high-fat diet + astaxanthin group, (n = 5 each). High-fat diet 
increased the rate of growth of bacterial count, (indicated by dotted lines), and 
addition of astaxanthin reduced it (indicated by arrows, p < 0.05). Groups com-
pared using Tukey’s multiple comparison test, rate of change by diet compared using 
Mann-Whitney’s U test. Cited from reference 24).
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being reduced in abundance in the elderly53. 
Depending on which species are involved, the results of changes in 
Clostridium abundance could be either beneficial or harmful. In the 
present study, Clostridium was found to increase during the high-fat 
diet, and was reduced toward normal levels by treatment with astaxan-
thin. Thus, the specific species affected may be those associated with 
dysbiosis caused by high fat intake, and not necessarily the beneficial 
varieties.
Genus Bifidobacterium
Bifidobacterium made up an extremely small amount of the total 
bacterial at less than 0.000006% (Figure 4). There was no significant 
difference between groups or before and after astaxanthin treatment. 
Since the standard deviation among individuals was so large, this 
result is only included for reference purposes.
Bifidobacterium is a genus of gram-positive anaerobic bacteria that 
is the first major colonizer of the human gastrointestinal tract and 
plays a significant role in maintaining intestinal health by preventing 
constipation, diarrhea, and colorectal cancer56. An abundance of the 
genus is closely correlated with the aging process57. Bifidobacterium 
colonizes newborns from birth and makes up a majority of infant 
microbiomes during their breast-feeding years, with species such as 
Bifidobacterium longum, B. breve, and B. bifidum being the most 
abundant. Their abundance falls to lower levels by adulthood (2-14% 
of total bacteria), and is significantly reduced in the elderly. Low 
levels of Bifidobacterium are associated with obesity and diabetes 
(types 1 and 2)54,57.
Bifidobacterium species have demonstrated numerous positive health 
effects and see common use as probiotics. B. longum and B. breve 
have both shown anti-obesity effects in a high-fat diet mouse model 
58): oral intake of both species resulted in a reduction in weight 
gain, reduced triglyceride accumulation in the liver, and increased 
cecal abundance of lactic acid bacteria; B. longum intake additionally 
reduced serum triglycerides. Similar effects are seen in B. bifidum59 as 
well as various other strains60. 
B. animalis subsp. lactis (AKA B. lactis), in addition to reducing 
weight gain, glycemic response, and fasting insulin levels in a high-fat 
diet mouse model, is also reported to reduce inflammation by down-
regulating tumor-necrosis factor expression in adipose and hepatic 
tissues61. B. lactis also mediates the effects of metabolic syndrome 
by improving glucose sensitivity, modulating the enteric flora, and 
producing a high amount of the short chain fatty-acid acetate62.
Bifidobacterium may also impact anxiety and stress (via the gut-brain 
axis). In a mouse model of chronic stress, mice that were resistant to 
social stress from exposure to aggression had a higher abundance of 
Bifidobacterium, and intake of a probiotic containing B. longum and 
B. infantis increased resilience to stress and mitigated its symptoms63. 
B. bifidum has also been reported to reduce signs of stress in a ma-
ternal separation mouse model: mice ingesting the probiotic showed 
significantly reduced susceptibility to stress, with lower serum corti-
costerone and improved intestinal permeability64.
The lack of any observed change from astaxanthin intake in contrast 
to the other genera examined may simply be due to the very low 
initial abundance, or perhaps indicate that a difference in metabolic 
pathways of Bifidobacterium prevents the positive effect of the carot-
enoid on its physiology.  
Other bacteria: Bacteroides, Prevotella, Clostridium leptum
Of the total bacterial, Bacteroides comprised less than 0.003%, a 
very small amount. The count was significantly increased by the high 
fat diet (p = 0.006). Addition of astaxanthin resulted in no significant 
difference.
Prevotella copies were also few, at 0.06%. The high fat diet markedly 
reduced bacterial count (p < 0.001). There was no significant change 
with the addition of astaxanthin.
Clostridium leptum copies comprised less than 1.6% of the total 
bacteria. It was significantly increased by the high fat diet (p = 
0.017). There was no significant difference with astaxanthin.
Phylum level analysis
The results of phylum level analysis are represented as the ratios of 
Firmicutes, Bacteroidetes, and other copy numbers, as shown in 
Figure 5.
Firmicutes accounted for 20% of total copies on Day 0, but 
increased to 40% on both Day 14 and Day 28 in the high-fat diet 
group (p < 0.001, Figure 6). There was no difference with the addi-
tion of astaxanthin. 
Bacteroidetes made up 45~50% of total copies on Day 0, but fell to 
20% on both Day 14 and Day 28 (p < 0.001 (Figure 7). There was 
no difference with the addition of astaxanthin.
changeS in enteric flora due to ingeStion of high-fat diet
Consumption of a high-fat diet increases the secretion of bile acids65, 
and causes various changes to the intestinal microbiota66. These 
changes are more pronounced in the large intestine than the small in-
testine67. High-fat diets weaken intestinal immunity, disrupt mucosal 
barrier function, and cause abnormal fermentation to occur in the 















Figure 4. Putative copy numbers of the genus Bifidobacterium
Results shown as percent of total bacterial copy number, mean ± standard devia-
tion. C: ordinary diet group, CA: ordinary diet + astaxanthin group, H: high-fat 
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Results pertaining to changes in gut microbiota caused by a high-fat 
diet have been reported in both animal and human studies. In a 
mouse model of type 2 diabetes (KK-Ay) Bacteroides is reduced and 
Clostridium coccoides tends to increase in the cecum70. In a mouse 
model of high-fat diet induced obesity, Bifidobacterium abundance 
in the cecum and feces was decreased71. In rats, Bacteroides and 
Prevotella were increased72. In humans, it has been reported that 
obese subjects likely consuming a high-fat diet carry a reduced 
amount of Bacteroides73. At the phylum level, Firmicutes have been 
found to increase while Bacteroidetes decrease73-75.
In this study, the results of the phylum level analysis generally 
agreed with those previously reported73-75. Due to the high-fat diet 
(Group H), Bacteroides, Clostridium coccoides, and Clostridium 
leptum amounts increased, while Streptococcus (lactic acid bacteria) 
decreased. The difference in the change of Bacteroides may be due 
to differences between host animal (rat vs. mouse), or perhaps dif-
ferences in testing methodology. However, Bacteroides species have 
previously been considered non-beneficial bacteria, so the results of 
the present study seem reliable. 
effectS of aStaxanthin on enteric flora
The following results regarding the effectiveness of astaxanthin were 
obtained from the animal study. First, astaxanthin can be expected to 
inhibit the short-term increase of Bacteroides (gram negative bacteria) 
caused by high-fat diet. Interestingly, the addition of astaxanthin 
increased the amount of Lactobacillus (lactic acid bacteria). Similarly, 
Streptococcus (lactic acid bacteria) was also increased by astaxan-
thin in the high fat diet. These results suggest that administering 
astaxanthin may improve enteric flora (inhibiting the overgrowth of 
gram-negative bacteria, increasing lactic acid bacteria).
For this experiment, astaxanthin was not administered via tube feed-
ing, but instead a fixed amount (0.02% astaxanthin) was mixed into 
the mice’s feed. While tube feeding would have allowed for more con-
sistency in dosage, the resulting damage to the upper gastrointestinal 
tract and increased stress on the mice would likely affect the intestinal 
microbiota. Individual differences were also increased: with mixed 
feed the dosage of astaxanthin depends on feed intake and is not a 
fixed quantity, however there is little stress on the mice.
Astaxanthin intake was estimated from the feed intake of the mice 
(mean body weight at 8 weeks: Group C 38~41 g, Group H 44~48 
g). The feed intake of Group C mice was about 3 g/day, consisting 
of 0.2 g/day of fat, 0.9 g/day of protein, and 1.0 mg/day of astaxan-
thin per mouse. The group H mice received about 5 g/day of feed 
consisting of 1.1 g/day of fat, 0.7 g/day of protein, and 0.6 mg/day 
of astaxanthin. The equivalent intake of astaxanthin for a human 




















Figure 5. Phylum Level Analysis
Ratios of bacterial abundance of the phyla Bacte-
roidetes, Firmicutes, and others, relative to total 
primer measurement for all bacteria. C: ordinary 
diet group, CA: ordinary diet + astaxanthin 
group, H: high-fat diet group, HA: high-fat diet 















*** p < 0.001
#   p < 0.001
#
*** *** ** **
Figure 6. Putative copy number of the phylum Firmicutes
Results shown as percent of total bacterial copy number, mean ± standard devia-
tion. C: ordinary diet group, CA: ordinary diet + astaxanthin group, H: high-fat 
diet group, HA: high-fat diet + astaxanthin group, (n = 5 each). Groups compared 
using Tukey’s multiple comparison test (*** vs. Day 0), rate of change by diet com-
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Figure 7. Putative copy numbers of the phylum Bacteroidetes
Results shown as percent of total bacterial copy number, mean ± standard devia-
tion. C: ordinary diet group, CA: ordinary diet + astaxanthin group, H: high-fat 
diet group, HA: high-fat diet + astaxanthin group, (n = 5 each). Groups compared 
using Tukey’s multiple comparison test (*** vs. Day 0), rate of change by diet com-
pared using Mann-Whitney’s U test (#, dotted lines). Cited from reference 24).
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and 800 mg/day for group HA, significantly higher than the typical 
supplement amounts of 6-24 mg/day. Thus, from this experiment it is 
not clear whether such an amount is suitable for human intake.
Approximately 95% of the astaxanthin remains in the intestinal tract 
unabsorbed. Less than 5% is absorbed and enters systemic circula-
tion, only some of which reaches the digestive tract again. Therefore, 
the majority of the astaxanthin likely acts directly on the intestinal 
microbiota. Any action by the astaxanthin on the intestinal tract or 
intestinal immunity has not yet been reported.
concluSion
The various bacterial cells that live in the human gut and form the 
intestinal microbiome number in the range of 600 trillion, 10 times 
the number of native cells that make up the human body itself. The 
makeup of the enteric flora shifts not only with age, but also due to 
diet, exercise, alcohol intake, smoking, and other lifestyle/environ-
mental factors. These changes play a role in health, contributing to 
things such as obesity, skin conditions, atopy, allergies, and carcino-
genesis. In order to maintain a youthful and healthy body, it is crucial 
to protect the health and stability of the enteric flora. Modern diets 
have led to an increase in the consumption of fats in recent years, and 
the resulting changes to the intestinal microbiota have been report-
ed70,71,76,77. Mitigating these changes is of great importance.
The mechanism by which astaxanthin prevented changes to the 
bacterial flora from a high-fat diet could not be determined within 
the scope of the presented studies. However, the following potential 
mechanisms are proposed: 
     1. It is possible that the antioxidant action of astaxanthin exerted a 
beneficial effect on the enteric flora. The change in bacterial com-
position induced by the high-fat diet, particularly the growth of 
gram-negative bacteria, created higher levels of oxidative stress. As 
astaxanthin intake improved the enteric flora, the increased oxidative 
stress may have been mitigated. This needs to be confirmed.
     2. Astaxanthin may be degraded by bacteria, producing low 
molecular weight substances which may then be responsible for the 
beneficial changes to the enteric flora in high-fat diets. It is necessary 
to examine the metabolic pathways of astaxanthin in the intestinal 
tract.
     3. Astaxanthin or its metabolites may have an effect on intestinal 
immunity. Markers related to intestinal immunity (e.g. IgA, defensin) 
need to be examined.
The intestinal tract of every individual is inhabited by an assortment 
of characteristic bacteria, which collectively form the enteric microbi-
ome. When fat intake increases due to changes in diet, the equilib-
rium between the various species that constitute the intestinal flora 
is altered. As a result, degenerative changes in lifestyle-related disease 
and aging of the host are promoted. Here we find that the intake of 
astaxanthin was able to inhibit these changes in the gut microbiota of 
mice induced by a high-fat diet. Even in humans, it is highly probably 
that the unabsorbed astaxanthin that remains in the intestinal tract 
exerts a positive effect against disturbance of the intestinal flora caused 
by a high-fat diet. 
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